– NORWAY, Bergen – Cytovation ASA, a clinical-stage immune-oncology company today announced that existing Board member Dr. Stein Christian Mohn (MD, Ph.D.) becomes the new Chair of Cytovation, representing Norwegian VC firm Sandwater.
“I am delighted to be taking on the role of Chairperson at Cytovation, having witnessed the company’s impressive progress during my time on the Board. I would like to welcome our new board members, each of whom brings considerable experience to Cytovation as we move into the next phase of development. CyPep-1 is a truly innovative product with strong potential in the treatment of solid tumors, and I look forward to working with the new Board and the Company’s highly experienced management team to help bring it to patients as quickly as possible.” said Board Chair, Dr. Stein Christian Mohn.
Current CEO of Mohn Drilling, Mohn combines over 16 years of industry experience with an extensive scientific background in biomedical research.
Representing Canica AS, a large, privately owned investment company operating out of Norway and Switzerland, which co-led the Series A round together with Sandwater, Cytovation has welcomed Dr. Øyvind Kongstun Arnesen (MD) to the Board. He has more than 10 years of clinical experience and an extensive track record in the pharmaceutical industry at BMS, Boehringer Ingelhe,im and Ultimovacs, where he was CEO from 2012 to 2020. He is Chairman of the Board of Curida, Hubro Therapeutics, and the Oslo Cancer Cluster.
Additional new Board members are Kjell Bernstrøm, representing Innovest AS, an investment group owned by the University of Bergen (where he was University Director) and Haukeland University Hospital; and two new independent directors, Hilde Hukkelberg and Liv H. Dyrnes.
Hilde Hukkelberg is a Board member for several companies and is Director, of the UK and Ireland for Innovation Norway, the Norwegian Government’s most important instrument for innovation and development of Norwegian enterprises and industry.
Liv H. Dyrnes has extensive financial and board experience and is CFO of Klaveness Combination Carriers ASA, a Norwegian maritime transportation company listed on the Oslo Stock Exchange.
About Cytovation
Cytovation ASA is a privately held, clinical-stage immune-oncology company focused on the development of CyPep-1, a first-in-class tumor membrane targeting agent. The company is a spin-off of the University of Bergen (Norway), the city where it is headquartered.
For more information: https://www.cytovation.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.